MQMehwish Qamar

Mehwish Qamar

*This is an algorithmically generated author record based on publicly available information.

Mehwish Qamar has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative Analysis of Human Cystatin C Levels in Migraine without Aura and Healthy Controls

    by Mariyam Khan, Maham Tahir, Sunia Hameed, Muhammad Umar Ali Khan, Mehwish Qamar, Mamoona Shafiq

    Objective: To compare the levels of human cystatin c (novel biomarker) as well as the association of other parameters in migraine patients without aura and healthy controls. Study Design: Cross-sectional, comparative study. Place and Duration of Study: The research was conducted at IMBB Physiology Department, University of Lahore, Lahore Pakistan, from May 2021 to Jun 2022. Methodology: After taking history, a detailed clinical examination was conducted of participants in both cases and controls of the study. A proforma was filled and a non-probability convenience sampling technique was used. The blood samples were drawn, centrifuged to isolate serum and analyzed concentration of serum cystatin C levels were measured by using enzyme linked immunosorbent assay (ELISA). SPSS version 22 was used for statistical analysis. Mann-Whitney U test was used to determine the median IQR values of both groups and p-valueResults: Among cases 19(47.5%) were male and 21(52.5%) were female. Mean age of cases and controls was 25.57±5.93 and 26.15±7.19 years. The most frequent occupation among cases and controls was student, doctors, nurses and house wives. Among cases only 3(7.5%) patients were currently smokers while among controls 3(7.5%) were currently smokers. Among cases body mass index of 11(27.5%) patients were 30 and 4(10%) participants in controls had body mass index as 30. The most frequent symptom was photophobia followed by nausea, phonophobia, vomiting and atypical features. All these features were significantly higher Conclusion: Study concluded that patients with migraine without aura have elevated levels of cystatin C in their

  • Open Access

    Correlation of Serum Anti-Mullerian Hormone with Ovarian Follicle Output Rate in Infertile Females: A Clomiphene Citrate Challenge Test

    by Syeda Fatima, Qanbar Naqvi, Ambreen Tauseef, Mehwish Qamar, Qudsia U. Khan, Tanzeela Akram, Muniza Saeed

    Failure to achieve a successful pregnancy after 12 months of unprotected intercourse is a pathology of the reproductive system known as infertility. Anti-Mullerian hormone (AMH) not only reflects the ovarian reserve but also is known to be a predictor of several assisted reproductive techniques, e.g., in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and clomiphene citrate challenge test. In this study, AMH levels are correlated with the follicular output rate after the clomiphene citrate challenge test. The objective of this study is to correlate AMH with the follicular output rate (FORT) after the clomiphene citrate challenge test. This study included a total of 80 primary and secondary infertile females, divided into early (18-30) and late (31-45) reproductive age groups either currently under clomiphene citrate treatment or advised to start clomiphene treatment, culled from out-patient department and centers of assisted reproductive techniques. On the third day of the menstrual cycle, blood samples were taken to determine serum AMH levels by ELISA. Then on the fifth day of the menstrual cycle, antral follicular counts were calculated through transvaginal ultrasound and oral tablet clomiphene citrate was started, and on day 12 and then on day 5, transvaginal ultrasound was repeated to record the number and diameter of dominant follicles. The pre-ovulatory (mature) follicle count was divided by the antral follicle count ×100 for calculating the FORT, which showed a negative Spearman Rho correlation (p = 0.048) with AMH. P-value ≤ 0.05 was considered significant. It is concluded that the most commonly administered drug, clomiphene citrate, may not be the treatment of choice for patients with high levels of AMH and may, in fact, interfere with the chances of achieving pregnancy. This study can provide guidelines to clinicians for patient counseling, given the results of the clomiphene citrate challenge test on the basis of AMH levels.